INTRODUCTION
Peripheral neuropathy is a significant adverse event in patients with multiple myeloma treated with thalidomide. Thalidomide-related peripheral neuropathy (TrPN) typically consists of symmetric paresthesias, with loss of tactile and pain response as well as numbness and muscle cramps. 1 Rates of neuropathy after thalidomide treatment vary from 15% to 70%, with the risk of neuropathy being related to the cumulative dose and duration of therapy.
2-6 Factors influencing the risk of neurotoxicity include prior neuropathy, age, 7 previous chemotherapy, and vitamin B 12 and/or folate deficiency. 8 The mainstay of TrPN prevention is dose reduction or withdrawal of thalidomide, which can lead to symptom resolution in up to 16 weeks 9 ; however, in some cases, neuropathy is irreversible.
At a pathologic level, TrPN is a lengthdependent, predominantly sensory axonal neuropathy affecting large and small fibers, 1, 5 but has also been classified as a ganglionopathy. 5, 10 Reduction in amplitude or absence of sensory nerve action potentials is the most common electrophysiologic alteration that can precede symptoms or worsen after thalidomide withdrawal and often does not resolve. 6, 11 Proposed mechanisms to explain TrPN include antiangiogenesis, direct toxic effects on the posterior root ganglia, and dysregulation of neurotrophin activity through nuclear factor-B.
JOURNAL OF CLINICAL ONCOLOGY
To date, there have been only a limited number of small studies investigating the genetic factors that associate with TrPN. [12] [13] In this study, we have sought to address this by investigating the genetic variation associated with risk of TrPN in two large clinical trials consisting of patients treated with thalidomide or vincristine and genotyped with a custom targeted panel of 3,404 single nucleotide polymorphisms (SNPs).
PATIENTS AND METHODS

Clinical Samples
Peripheral-blood DNA samples were obtained from 1,495 patients presenting with myeloma derived from two randomized clinical trials (Medical Research Council Myeloma-IX, n ϭ 993; and Dutch-Belgian HematoOncology Cooperative Group [HOVON] -50/German-Speaking Myeloma Multicenter Group [GMMG] -HD3, n ϭ 502) comparing standard treatment with thalidomide-containing regimens. Peripheral neuropathy was assessed using National Cancer Institute Common Toxicity Criteria version 2.0. Neuropathy events were only considered after induction therapy and not during maintenance. In a discovery set analysis, we compared genotype results from 194 Myeloma-IX patients with neuropathy after exposure to thalidomide with 416 control patients treated with thalidomide who did not develop neuropathy. Patient cases and controls were matched for age and sex. As validation, we compared 74 thalidomide-treated patients with neuropathy from the HOVON-50/GMMG-HD3 trial with 176 thalidomide-treated controls. We then carried out a comparison using patients with neuropathy Ն grade 2 in the Myeloma-IX trial; 75 patients with neuropathy were compared with 297 matched controls; in the HOVON-50/GMMG-HD3 analysis, 49 patients with neuropathy Ն grade 2 were compared with 176 controls. In the nonthalidomide arms, neuropathy events were also seen after vincristine exposure. We carried out a nested case-control comparison using 76 patients with vincristine-related neuropathy from Myeloma-IX compared with 307 controls. In the HOVON-50/GMMG-HD3 cohort, we compared genotypes from 26 patients with vincristine-related neuropathy with genotypes from 226 controls. To ensure homogeneity of allelic frequencies, only patients of European descent were included.
Clinical Trials
The Myeloma-IX study comprised two random assignments. The first random assignment included an intensive pathway for younger, fitter patients comparing cyclophosphamide (500 mg orally weekly), vincristine (0.4 mg intravenous on days 1 to 4), doxorubicin (9.0 mg/m 2 on days 1 to 4), and dexamethasone (40 mg on days 1 to 4 and 12 to 15) with cyclophosphamide, thalidomide, and dexamethasone (CTD) using the same doses of cyclophosphamide and dexamethasone combined with a target dose of thalidomide 200 mg. The second random assignment, for older, less fit patients, compared an attenuated dose of CTD (thalidomide 100 mg) with melphalan (7.0 mg/m 2 once daily orally on days 1 to 4 every 28 days) and prednisolone. The HOVON-50/GMMG-HD3 study randomly assigned patients to either three cycles of vincristine (0.4 mg intravenous rapid infusion on days 1 to 4), doxorubicin (9 mg/m 2 intravenous rapid infusion on days 1 to 4), and dexamethasone (40 mg orally on days 1 to 4, 9 to 12, and 17 to 20) or the same regimen but with thalidomide (200 mg, but could be escalated to 400 mg) replacing the vincristine (Fig 1A) .
Genotyping and SNP Selection
DNA was extracted from frozen WBC pellets using Flexigene kit (Qiagen, Crawley, United Kingdom) and quantified using a NanoDrop Spectrophotometer (NanoDrop Products, Wilmington, DE). Genotyping was performed using an Affymetrix Targeted genotyping True-tag (BOAC) array (Affymetrix, Santa Clara, CA).
14-16 SNPs were selected using a hypothesisdriven strategy targeting genes and SNPs with previously described associations or putative functional effects. There was no sample ascertainment bias between patient cases and controls because genotyping was performed before access to demographic and phenotypic data.
Statistical Analyses
Departures from Fisher's exact Hardy-Weinberg equilibrium at a level of P Ͻ .0001 and bias in missing data were controlled for each SNP. A CochranArmitage trend test and a Fisher's exact test were performed to evaluate odds ratios. Genomic inflation factor was evaluated based on the median To generate a predictive strategy based on genetic variation, recursive partitioning analysis was performed using the Willows program. 22 Redundant associated SNPs in linkage disequilibrium were filtered, and recursive partitioning was performed on a training set consisting of two thirds of the Myeloma-IX data set to create an initial predictive tree; this tree was pruned at level of P Ͻ .001 to a smaller number of classifier SNPs. The final predictive tree was then assessed for its ability to correctly classify the remaining one third of the Myeloma-IX and HOVON-50/GMMG-HD3 data sets.
In an alternate approach, a risk score classifier was generated based on the summation of the associated at-risk and protective SNPs. Using a training set of two thirds of the Myeloma-IX data set, the log 10 (odds ratios) of the associated SNPs for each patient was summed. This scoring system was assessed for its ability to correctly classify patients at risk in the remaining third of the Myeloma-IX and HOVON-50/GMMG-HD3 data sets.
RESULTS
Clinical Results
The clinical characteristics and demographics of the Myeloma-IX trial patients across the whole trial (Table 1) were com- 1B) . In this analysis, 31.8% of patients developed neuropathy (grade Ն 1, 31.8%; grade Ն 2, 11%; and grade Ն 3, 3.6%) after exposure to thalidomide. The median time to neuropathy was 8 weeks. A higher frequency of grade Ն 3 neuropathy was seen in older patients (5%). In patients exposed to vincristine, 33.6% developed neuropathy in a median of 8 weeks. In contrast, 6.4% patients not exposed to thalidomide or vincristine developed grade 1 neuropathy in a median of 6 weeks (Data Supplement). We did not find significant differences between patients with and without neuropathy for previously described risk factors such as immunoglobulin type and age. 7 Assessing the rates of TrPN based on the ISS stage, we found that tumor burden is not related to risk. Similarly, because fluorescent in situ hybridization variants are distributed evenly between patients with and without neuropathy, the pathogenic subtype does not seem to contribute to risk. Interestingly, we identified increased rates in men compared with women, the cause for which is uncertain. To address the hypothesis that patients who respond best to thalidomide are more sensitive to TrPN, we examined the relationship of neuropathy to response during induction in the Myeloma-IX study. Although we saw a greater percentage of complete responses and very good partial responses in patients lacking neuropathy, the difference did not reach statistical significance (Pearson 2 test, P ϭ .55; Fig 2A) . Additionally, we did not see a significant relationship between response and time to neuropathy (Fig 2B) . These clinical data show the variability of risk between patients and the lack of any simple clinical variants that can predict risk.
Genotyping Results
To address the hypothesis that genetic variation mediates the risk of TrPN, we compared the genetic contribution of patients who developed neuropathy with that of patients who did not develop neuropathy. The initial analysis included all patients with TrPN, and a secondary analysis was carried out using only patients with neuropathy of grade Ն 2. SNPs significantly associated with TrPN (P Ͻ .01) in the Myeloma-IX data set are listed in Table 2 . The associated SNPs were similar in grade Ն 1 and grade Ն 2 analyses, indicating a common mechanism for thalidomide neuropathy across the groups.
Findings from the Myeloma-IX study were validated in a second comparable study, the HOVON-50/GMMG-HD3 trial, and significantly associated SNPs in this study are provided in the Data Supplement. To cross validate the findings between the studies, we investigated whether a significantly associated SNP in either study alone (permutated P Յ .05) was associated with risk in the second study. This included 103 SNPs from the Myeloma-IX study and 82 SNPs from HOVON-50/GMMG-HD3. Using this approach on TrPN grade Ն 2, we found five cross-validating SNPs in different genes (Table 3) . It should be noted, however, that the size of the validation set may be underpowered to validate all associations in the discovery set. Associated regulatory region SNPs were analyzed for a relationship with gene expression (Data Supplement).
Haplotype analysis (see haplotype-tagging SNPs) of ABCC1 variants with TrPN reveal that the main effect can be attributed to a two-SNP haplotype involving SNPs rs246217 and rs246218 (Data Supplement). Analysis of the 12 genotyped SNPs in the ABCC2 gene reveals a four-SNP haplotype, with three SNPs additively contributing to risk of TrPN (Data Supplement).
To investigate whether the observed associations with thalidomide were drug specific, we sought to contrast findings with a parallel study in patients treated with vincristine. Significantly associated SNPs associated with vincristine neuropathy in the Myeloma-IX data set are listed in Table 4 and the Data Supplement.
Using inherited genetic variation as a clinical means of risk stratification to adjust thalidomide dose is an important clinical goal, and in an effort to build a predictive model based on a limited number of predictive SNPs, we examined two classification methods. In the first method, we used recursive partitioning to create a predictive tree. This tree predicted patient cases and controls with a sensitivity of 38% and a specificity of 31% in the Myeloma-IX validation set and a sensitivity of 30.7% and a specificity of 81.6% in the HOVON-50/GMMG-HD3 data set (Data Supplement). The second method of cumulative risk score predicted patient cases of neuropathy with a sensitivity of 100% and a specificity of 77.8% in the Myeloma-IX validation set and sensitivity of 60% and a specificity of 70.5% in the HOVON-50/ GMMG-HD3 data set (Data Supplement). 
DISCUSSION
Using a hypothesis-driven candidate gene approach, we show for the first time that there is a significant genetic contribution to the risk of TrPN. Thalidomide is used in the treatment of a number of diseases where the increased production of TNF-␣ is thought to be pathogenically important, but the benefits of thalidomide can be limited by the onset of TrPN. This study, one of the largest pharmacogenomics studies of its kind to date, 22a,22b has allowed us to identify genetic variants that contribute to TrPN risk. These findings provide important insights into the therapeutic management of these patients and will stimulate further research into protective strategies for patients treated with thalidomide. Although we considered taking a genomewide approach to identify such genetic variation, it was not applicable because of issues with statistical power. In addition, the candidate gene approach allowed us to examine our candidate regions in greater detail than could be achieved with mapping arrays such as the Affymetrix 500k (Affymetrix) or Illumina 550k (Illumina, San Diego, CA).
The doses of thalidomide used in the study were moderate at 100 to 200 mg, and the neuropathy occurred early, after a median of three cycles of treatment. This group of patients is distinct from the group who develop neuropathy associated with prolonged exposure, which is dependent on the total dose of thalidomide received and was not studied here. We did not identify any simple clinical parameters that were associated with early-onset neuropathy, and patients were not unduly sensitive to thalidomide, with response rates being similar in patients and controls. We cannot be certain about associations with other comorbid conditions such as diabetes, diet, and alcohol consumption because the data were not systematically collected. Patients with pre-existing neuropathy were excluded.
A number of ATP-binding cassette (ABC) transporter genes were linked with TrPN. Both ABCC1 SNPs rs246217 and rs246218 are intronic but lie within transcription binding domains and may mediate levels of expression of ABCC1. Two SNPs in ABCC2 (rs3740066 and -24 CϾT rs717620) are also associated with neuropathy risk. rs717620 has been associated with decreased ABCC2 function in vitro [23] [24] [25] and toxicity in other systems, 26 whereas rs3740066 may modulate substrate specificity via codon usage, therefore influencing the translation rate. 27 Also, in ABCA1, rs363717 is a cross-validating SNP and is found in the binding domain of the microRNA hsa-miR-299. Weaker associations were 30 both of which are active in neuronal function.
We saw a number of associations with other ADME (absorption, distribution, metabolism, excretion) genes, including a promoter SNP in FMO6 (rs1736565) and the ion channel gene SLC12A6 (rs7614902), previously associated with peripheral neuropathy. 31 It has been suggested that CYP2C19 plays a role in thalidomide metabolism [32] [33] [34] ; however, it is now known that thalidomide breakdown is dependent on spontaneous nonenzymatic degradation.
35 Consistent with this, we found no association of neuropathy risk with functional variants in CYP2C19 or other genes in the CYP2C subfamily. No consistent association was seen with common N-acetyltransferase 2 (NAT2) variants, as previously reported.
13
Pathway analysis of the TrPN-associated SNPs highlights the association with genes involved in the development of the central and peripheral nervous system. A conserved promoter SNP (rs1611753), which affects the expression of the gene SPRR1A, was significantly associated with TrPN in HOVON-50/GMMG-HD3 samples. The SPRR1A gene is expressed by axotomized neurons and promotes axonal outgrowth. 36 Variation in neurologic genes may dictate the ability of a damaged neuron to undergo repair and may mediate risk of neuropathy.
We also describe associations with SNPs in genes mediating neuro-inflammation, with approximately 35% of the TrPNassociated SNPs having an inflammatory role. We found associations with SERPINB2 (rs6103), a gene induced in injured neurons, 37 and PPARD (rs2076169), which may also indicate a role of neuroinflammation in the pathology mechanism.
We found 20% of the TrPN-associated genes in this study to have some transmembrane transporter activity, consistent with a hypothesis where variants in transmembrane transporter genes mediate their effects at the level of the peripheral nerve. 38 At this site, they negatively impact on the ability of the dorsal root ganglions to repair themselves after exposure to the toxic effects of thalidomide and/or promote neuro-inflammatory change. Prophylactic pharmacologic therapies aimed at modulating ion channel activity may prove useful in reducing neurotoxicity caused by axonal membrane ion channel variation.
39,40
The genetic mechanisms underlying thalidomide and vincristine neuropathy seem distinct. SNP associations with vincristine neuropathy include rs2082382 and rs1042714 in ADRB2. Association with vincristine neuropathy was observed in a highly conserved promoter SNP (rs7214723) in CAMKK1, which is expressed at higher levels in neurons resistant to oxidative stress. We also found an association with nonsynonymous SNPs in CYP2C9 (rs1934951) and NFATC2 (rs228832), conserved intronic SNPs in ID3 (rs1555026) and SLC10A2 (rs2301157), and in CYP2C8 (rs1058932), which is located in the binding site for the microRNA hsa-miR-96. Interestingly, we saw little overlap of the genes associated with TrPN and those associated with vincristine-related neuropathy. We propose that this is indicative of a fundamentally different pathologic mechanism between these neuropathies. In contrast, similar TrPN-associated genes have been seen in studies investigating peripheral neuropathy in response to paclitaxel, bortezomib, and docetaxel, which result in sensory peripheral neuropathies as opposed to the sensorimotor neuropathy associated with exposure to the vinca alkaloids and paclitaxel.
We show that simple clinical factors do not allow the identification of patients at greater risk of neuropathy after thalidomide exposure, for whom dose adjustment or cessation of therapy would be appropriate. Consequently, we have attempted to define a limited number of SNPs that can identify high-risk patients suitable for more intensive clinical monitoring. In this approach, we have used two risk classification methods, both of which can identify patients at increased risk, but the predictive value of these is not adequate to totally avoid thalidomide usage. However, this approach can be used to identify patients requiring greater clinical vigilance and suitable counseling.
The poor risk prediction in our classifiers is a result of a number of limitations, including naive assumptions in modeling methods (the risk score method assumes interactions to be solely additive, whereas recursive partitioning method interactions are assumed to be unidirectional); the fact that hypothesis-driven approaches do not consider all variation contributing to an outcome; population-specific effects; and the impact of rare variation. Despite these drawbacks, the limited number of SNPs identified in this study can be used as a simple and useful method for identifying patients at high risk of TrPN, who in turn may benefit from greater clinical vigilance. 
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Glossary Terms
ADME (absorption, distribution, metabolism, excretion): Gene pathways important in the absorption, distribution, metabolism, and excretion of a pharmaceutical compound within an organism. These genes influence the drug levels and kinetics of drug exposure to tissues and can influence the performance and pharmacologic activity of the compound as a drug.
Allele: an alternative form of a gene (in diploids, one member of a pair) that is located at a specific position on a specific chromosome.
FISH (fluorescent in situ hybridization):
In situ hydridization is a sensitive method that is generally used to detect specific gene sequences in tissue sections or cell preparations by hybridizing the complementary strand of a nucleotide probe to the sequence of interest. FISH uses a fluorescent probe to increase the sensitivity of in situ hybridization.
Haplotype-tagging SNPs:
Markers that are statistically associated with and are therefore considered to be representative of a set of SNPs within a particular region. Using this technique, the identification of a few alleles of a haplotype block allows for the identification all other polymorphic sites in this region of linkage disequilibrium.
Hardy-Weinberg equilibrium:
A state in which genotype frequencies and ratios remain constant from generation to generation and in which genotype frequencies are a product of allele frequencies. A randomly mating population tends toward a HardyWeinberg equilibrium state if there are no mutations, migrations, or environmental factors favoring particular genotypes.
Pharmacogenomics:
The study of how a person's genome can affect their reaction to medications.
Recursive partitioning: Multivariable analysis that generates a clinically intuitive decision tree model in which the population is divided into prognostic subgroups. This is achieved through multiple dichotomous divisions on the basis of a set of independent variables.
Risk score: A simplified version of a prognostic model, where scores are assigned to each risk factor (eg, based on rounded regression coefficients).
SNP (single nucleotide polymorphism):
Genetic polymorphisms are natural variations in the genomic DNA sequence present in greater than 1% of the population, with SNP representing DNA variations in a single nucleotide. SNPs are being widely used to better understand disease processes, thereby paving the way for genetic-based diagnostics and therapeutics.
Validation set: Samples used in evaluating performance of a classifier. The validation set is formed by the units not used in developing the classifier (ie, the training set and test set).
